SCHEMBL6604980

SCHEMBL6604980

Clc1cc2cc[nH]c2c2cccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 2/20 0.51
▸ CCR8 P51685 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.50
▸ KDM4E B2RXH2 4/20 0.43
▸ LMNA P02545 4/20 0.43
▸ HSP90AA1 P07900 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ MMP14 P50281 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ TP53 P04637 3/20 0.43
▸ ALOX15 P16050 3/20 0.43
▸ SLC6A2 P23975 3/20 0.43
▸ HTT P42858 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ ALOX12 P18054 2/20 0.43
▸ OPRK1 P41145 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31426926 0.81 AXL (0.41) CCR1CCR8L3MBTL1ALDH1A1KDM4E
SCHEMBL28889099 0.75 AHR (0.48) ALDH1A1CYP1A2AHRNR4A2IKBKB
SCHEMBL10829012 0.75 PARP1 (0.47) CCR1CCR8L3MBTL1ALDH1A1KDM4E
SCHEMBL2559892 0.70 PARP1 (0.43) L3MBTL1ALDH1A1LMNAHSP90AA1AXL
SCHEMBL2087722 0.69 MAPT (0.54) ALDH1A1KDM4ELMNAHSP90AA1MAPT
SCHEMBL29852620 0.69 MAPT (0.54) ALDH1A1KDM4ELMNAHSP90AA1MAPT
SCHEMBL8600442 0.69 AXL (0.46) KDM4ELMNAMAPTAXLNUDT1
SCHEMBL3167612 0.69 CCR1 (0.53) CCR1CCR8L3MBTL1ALDH1A1KDM4E
SCHEMBL1159986 0.68 LMNA (0.58) CCR1CCR8L3MBTL1ALDH1A1KDM4E
SCHEMBL504765 0.68 CCR1 (1.00) CCR1CCR8L3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109809-B1 PYRROLOQUINOLINES FOR TREATMENT OF OBESITY CEREBRUS PHARM LTD (GB) 2004-11-17 — — EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 — — US disclosed
Send feedback